Background The genetic and clinical heterogeneity of breast cancer makes the identification
of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively …

Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …

Background The heterogeneity of breast cancer makes identifying effective therapies challenging.
The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-…

Importance Pathologic complete response (pCR) is a known prognostic biomarker for long-term
outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in …

Learning Objectives After completing this course, the reader will be able to: Evaluate the level
of evidence to inform decision making for the treatment radiation induced sarcoma of the …

Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their
unique and pharmacologically important properties, cell-derived exosome nanoparticles have …

BACKGROUND: Accurate intraoperative pathologic examination of sentinel lymph nodes (SLNs)
has been an important tool that can reduce the need for reoperations in patients with …

Importance Residual cancer burden (RCB) distributions may improve the interpretation of
efficacy in neoadjuvant breast cancer trials. Objective To compare RCB distributions between …

Mammosphere culture of breast cancer cell lines is an important approach used for enrichment
of cancer stem cells (CSCs), which exhibit high tumorigenicity and chemoresistance …

HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we
report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 …